| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 08/31/2004 | US6784198 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
| 08/31/2004 | US6784187 8-carboxamido-2,6-methano-3-benzazocines |
| 08/31/2004 | US6784179 Tetracyclic derivatives, process of preparation and use |
| 08/31/2004 | US6784174 Inhibitors of the production of cytokines such as tnf |
| 08/31/2004 | US6783769 Layer of a tolterodine containing a matrix composition disposed on film, matrix is solid solution of copolymer of ethyl acrylate and methyl methacrylate and about 5% trimethylammonium ethyl methacrylate chloride and plasticizer |
| 08/31/2004 | US6783761 Hormone inhibitors for inducing antibodies against gonadotropin-releasing hormone, comprises fusion peptide of helper t-cell peptide epitope and immunomimic peptide epitope |
| 08/31/2004 | CA2194369C Methods and compositions for the specific coagulation of vasculature |
| 08/26/2004 | WO2004072643A2 Diagnostics and therapeutics for diseases associated with glucagon-like peptide 2 receptor (glp2r) |
| 08/26/2004 | WO2004072282A1 Nephropathy-associated gene |
| 08/26/2004 | WO2004072043A1 Benzyl urea and thiourea derivatives useful as androgen antagonists |
| 08/26/2004 | WO2004072020A1 Hydroxy-tetrahydro-naphthalenylurea derivatives |
| 08/26/2004 | WO2004072016A1 Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
| 08/26/2004 | WO2004071533A1 Preparation for topical administration |
| 08/26/2004 | WO2004071381A2 Drugs containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds |
| 08/26/2004 | WO2004071378A2 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a) |
| 08/26/2004 | WO2003070911A3 Rna interference mediated inhibition of type 1 insulin-like growth factor receptor (igf-1r) |
| 08/26/2004 | WO2003055440A3 Compositions and methods for the treatement of immune related diseases |
| 08/26/2004 | WO2002030268A3 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer |
| 08/26/2004 | US20040167341 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 08/26/2004 | US20040167196 Treatment of benign prostatic hyperplasia |
| 08/26/2004 | US20040167176 Tricyclic compounds useful as angiotensin II agonists |
| 08/26/2004 | US20040167160 Skin disorders; controlling cell differentiation; antidiabetic agents; cardiovascular disorders; anticancer agents; central nervous system disorders |
| 08/26/2004 | US20040167141 Anticancer agents; antidiabetic agents; Alzheimer's disease |
| 08/26/2004 | US20040167137 Xanthine phosphodiesterase V inhibitors |
| 08/26/2004 | US20040167133 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/26/2004 | DE10306202A1 2-(hetero)aryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or especially pain is NMDA antagonist |
| 08/26/2004 | CA2515418A1 Hydroxy-tetrahydro-naphthalenylurea derivatives |
| 08/26/2004 | CA2514244A1 Benzyl urea and thiourea derivatives useful as androgen antagonists |
| 08/25/2004 | EP1449539A2 Prophylactic or therapeutic use of a Fas antagonist to inhibit Fas-mediated apoptosis |
| 08/25/2004 | EP1448591A1 17alpha-alkyl-17beta-oxy-estratrienes and intermediates for the production thereof, and use of said 17alpha-alkyl-17beta-oxy-estratrienes for producing medicaments and pharmaceutical preparations |
| 08/25/2004 | EP1448566A2 Chemokine receptor antagonists and methods of use thereof |
| 08/25/2004 | EP1448545A1 Nf-kb inhibitors |
| 08/25/2004 | EP1448544A1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 08/25/2004 | EP1448542A1 6-hydroxy isoflavones, derivatives and medicaments involving same |
| 08/25/2004 | EP1448535A1 Benzamide and heteroarylamide as p2x7 receptor antagonists |
| 08/25/2004 | EP1448531A1 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
| 08/25/2004 | EP1448513A1 Biphenyl-derivatives as p38-kinase inhibitors |
| 08/25/2004 | EP1448234A1 Formulations comprising a cephalosporin compound and their use in treating bacterial infections in cats and dogs |
| 08/25/2004 | EP1448232A1 Anti-proliferative composition |
| 08/25/2004 | EP1448217A1 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| 08/25/2004 | EP1448216A2 Methods for epitope-specific and cytokine/anticytokine combination immunotherapies for modulation of pathogenic immune responses in immune mediated diseases |
| 08/25/2004 | EP1448212A1 Mint extract pharmaceutical compositions |
| 08/25/2004 | EP1448195A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation |
| 08/25/2004 | EP1448191A1 Ilk inhibitors for the treatment of renal disease |
| 08/25/2004 | EP1448190A2 Salts formed of an at1-receptor antagonist and a cardiovascular agent |
| 08/25/2004 | EP1448181A1 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 08/25/2004 | EP1448168A1 Pharmaceutical formulation comprising bicalutamide |
| 08/25/2004 | EP1448150A2 Treatment of hyperproliferative diseases using active vitamin d analogues |
| 08/25/2004 | EP1353939B1 Tetrapeptide regulating prostate functions and its compositions and uses |
| 08/25/2004 | EP1343764B1 Urea and urethane derivatives as integrin inhibitors |
| 08/25/2004 | EP1212067A4 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 08/25/2004 | EP1169337B1 Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction |
| 08/25/2004 | EP1083903B1 Bridged indenopyrrolocarbazoles |
| 08/25/2004 | EP0973769B1 Process for preparing eprosartan |
| 08/25/2004 | CN1524082A Beta-amino tetrahydroimidazo (1,2-a) pyrazines and ahydrotrioazolo (4,3-a) pyrazines as dipeptidyl idase inhibitors for the treatment or prevention of diabetes |
| 08/25/2004 | CN1524080A Phthalatyinone-piperidino-derivatives as pde4 inhibitors |
| 08/25/2004 | CN1524079A Novel sulfamides and their use as endothelin receptor antagonists |
| 08/25/2004 | CN1524078A Antagonists of mcp-1 function and methods of use thereof |
| 08/25/2004 | CN1523989A Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 08/25/2004 | CN1523015A 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines |
| 08/25/2004 | CN1522743A Kidney disease therapeutic pharmaceutical |
| 08/25/2004 | CN1522733A Traditional Chinese medicine liquid for treating calculus |
| 08/25/2004 | CN1522727A Prostate hyperplasia pharmaceutical and method for making same |
| 08/25/2004 | CN1522724A Traditional Chinese medicine pill for treating acute and chronic nephritis |
| 08/25/2004 | CN1163509C RET ligand (RetL) for stimulating neural and renal growth |
| 08/25/2004 | CN1163466C Substituted oxobutyric acid derivative as matrix metalloprotease inhibitor |
| 08/25/2004 | CN1163236C Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis |
| 08/25/2004 | CN1163224C Drugs for improving vesical excretory capacity |
| 08/25/2004 | CN1163222C Drug delivery system for releasing two or more active substance |
| 08/24/2004 | US6780997 Such as dibenzyl(a,3-o-isopropylidiene-3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridyl) hydroxymethylphosphonate which functions like pyridoxal-5'-phosphate in vivo; drug screening; antidiabetic agents |
| 08/24/2004 | US6780994 Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia |
| 08/24/2004 | US6780972 Reacting an acid addition salt of a basic starting peptide in the presence of a diluent in a mixed bed ion exchanger; forming a free peptide; and then forming the desired acid addition salt of the peptide |
| 08/24/2004 | US6780968 Neurokinin-2 (nk-2) antagonists useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, asthma, or pain |
| 08/24/2004 | US6780884 Derivating of tryptamine and analogous compounds and pharmaceutical formulations containing them |
| 08/24/2004 | US6780872 Asthma; antiepileptic agents; sexual disorders |
| 08/24/2004 | US6780869 Selective inhibitor of cox-2; antiinflammatory agent |
| 08/24/2004 | US6780867 Thienopyrimidines |
| 08/24/2004 | US6780859 For therapy of diabetes, obesity, impaired glucose tolerance, gastrointestinal disorders, hypertriglyceridemia, hypercholesteolemia, atherosclerotic disorders, or cardiovascular disorders |
| 08/19/2004 | WO2004069834A1 Tricyclic compound, process for producing the same, and use |
| 08/19/2004 | WO2004069833A1 Fused-ring pyridine derivative, process for producing the same, and use |
| 08/19/2004 | WO2004069808A1 Acrylamide derivative, process for producing the same, and use |
| 08/19/2004 | WO2004069806A2 Substituted 2-aminoimidazoles, method for the production thereof, their use as a medicament or as a diagnostic reagent, and medicament containing these compounds |
| 08/19/2004 | WO2004069805A1 Bis(hetero)aryl carboxamide derivatives for use as pgi2 antagonists |
| 08/19/2004 | WO2004069798A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
| 08/19/2004 | WO2004069788A1 Carboxylic acid compounds |
| 08/19/2004 | WO2004069294A1 Injectable gel-forming compositions based on cross-linked and non-cross-linked polymers and the use thereof |
| 08/19/2004 | WO2004069232A2 Egfr tyrosine kinase inhibitor for treating cardiovascular dysfunction |
| 08/19/2004 | WO2004069165A2 Methods and compositions for the treatment of gastrointestinal disorders |
| 08/19/2004 | WO2004047830A3 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction |
| 08/19/2004 | WO2004006756A3 THERAPIES FOR RENAL FAILURE USING INTERFERON-β |
| 08/19/2004 | WO2003094853A3 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 08/19/2004 | WO2003092585A3 Controlled release compositions of estradiol metabolites |
| 08/19/2004 | WO2003072720A3 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| 08/19/2004 | WO2003049702A8 Vanilloid receptor ligands and their use in treatments |
| 08/19/2004 | US20040162433 Lipoxin A4 analogs |
| 08/19/2004 | US20040162314 Enzyme inhibitors of phosphordiesterase 4 having minimal side effects; antiinflammatory agents; antiallergens; asthma; neurodegenerative disorders; antidiabetic agents; pain; anti-tumor, -carcinogenic and -arthritic agents |
| 08/19/2004 | US20040162313 Heterocyclic derivatives |
| 08/19/2004 | US20040162304 Estrogen receptor modulators |
| 08/19/2004 | US20040162291 For therapy of cardiovascular disorders and erectile dysfunction |
| 08/19/2004 | US20040162290 For therapy of cancer, benign prostatic hypertrophy or myoma of the uterus, endometriosis, polycystic ovarian disease, uterine fibroids or precocious puberty, lupus erythematosis, irritable bowel syndrome, premenstrual syndrome, hirsutism |